Breast cancer patients whose tumors test positive for the proteinHER-2 and test negative for hormone receptors have a high risk oftreatment failure after chemotherapy -- and the most common site ofcancer recurrence after treatment failure is the brain, Mayo Clinicresearchers reported at the San Antonio Breast Cancer Symposium.
More...